Active ingredientDidanosineCat. No. P-D100-001CAS 69655-05-6Family · Pharmaceutical analytical standards
Didanosine
A nucleoside analogue antiretroviral (ddI) that blocks HIV reverse transcriptase: its antiviral activity was discovered at the US National Cancer Institute by Samuel Broder, Hiroaki Mitsuya and Robert Yarchoan. Approved in the United States on 9 October 1991, it was the second anti-HIV drug. This family brings together the active ingredient, pharmacopoeial impurities and labelled standards.
Did you know?Because it is easily destroyed by stomach acid, the first approved formulation was a chewable tablet that also contained a buffering antacid.
Go to the active ingredient →Active ingredientDidanosineCat. No. P-D100-001CAS 69655-05-6
Pharmacopoeial impurityDidanosine EP Impurity FCat. No. P-D100-002CAS 42867-68-5
Pharmacopoeial impurityDidanosine EP Impurity GCat. No. P-D100-003CAS 4097-22-7
Isotopically labelledDidanosine-d2Cat. No. P-D100-007
Pharmacopoeial impurityDidanosine EP Impurity ACat. No. P-D100-008CAS 68-94-0No product matches your search.
EDQM standards 4
The official European Pharmacopoeia standards for this family.
Reference substanceDidanosine CRSEDQM code Y0000439Family DidanosineImpurityDidanosine impurity A CRSEDQM code Y0000441Family DidanosineImpurityDidanosine impurity G CRSEDQM code Y0000442Family DidanosineNeed a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.